While detecting viruses, such as the SARS-CoV-2, various doubts might arise: for example whether a sample was really negative or whether the assay was sensitive enough to detect it. RNA derived from COVID-19 nasal swab samples can considerably differ in quality, quantity, and viral titers, thereby making the accurate detection of the virus difficult.

Tecan’s Crescendo cDNA Synthesis for qPCR transforms total RNA to cDNA, and then amplifies with patented SPIA® technology, performing well even for degraded samples such as nasal swabs.

The figure below shows that Crescendo cDNA Synthesis performs better than standard first-strand synthesis method and successfully detects SARS-CoV-2 from nasal swab. Crescendo cDNA Synthesis used in conjunction with CDC-developed TaqMan SARS-CoV-2 probes, improves detection of SARS-CoV-2 even with high human RNA background

Crescendo cDNA™ Synthesis for qPCR

Image Credit: Tecan

Crescendo cDNA Synthesis has been developed to offer considerably improved sensitivity over the standard single-strand cDNA synthesis technique, thus enabling users to be confident in interrogating the samples across a wide range of input RNAs differing in quality and quantity.

Features

  • Dependable cDNA Dependable cDNA synthesis even from small amounts of poor quality total RNA
  • Produces micrograms of cDNA for downstream applications
  • Wide input range varying from 500 pg to 50 ng enables access to any sample

For Research Use Only. Not for use in diagnostic procedure